GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Common Stock

MindBio Therapeutics (XCNQ:MBIO) Common Stock : C$5.15 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Common Stock?

MindBio Therapeutics's quarterly common stock increased from Jun. 2024 (C$4.99 Mil) to Sep. 2024 (C$5.03 Mil) and increased from Sep. 2024 (C$5.03 Mil) to Dec. 2024 (C$5.15 Mil).

MindBio Therapeutics's annual common stock increased from Jun. 2022 (C$4.06 Mil) to Jun. 2023 (C$4.79 Mil) and increased from Jun. 2023 (C$4.79 Mil) to Jun. 2024 (C$4.99 Mil).


MindBio Therapeutics Common Stock Historical Data

The historical data trend for MindBio Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Common Stock Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Common Stock
- 4.06 4.79 4.99

MindBio Therapeutics Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.83 4.77 4.99 5.03 5.15

MindBio Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


MindBio Therapeutics Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough micro dosing studies. Geographically, the company's activities take place in Australia.